ArticlePituitary2025
USP8, USP48, BRAF and TP53 mutations in crooke cell adenoma.
Article in Pituitary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeCrooke cell adenomas (CCAs) are rare histological subtype of corticotroph pituitary adenomas (cPAs) commonly related to worse prognosis in patients. Notable progress in understanding of the molecular background of cPAs has been made recently but biology of CCAs remains poorly recognized. Results of our previous study suggested distinct frequency of the known recurrent mutations in CCAs than in sparsely and densely granulated cPAs. Thus, the aim was to determine the prevalence of USP8, USP48, BRAF and TP53 variants in a relatively large retrospective group of patients diagnosed with CCA.
methodsDNA was isolated from formalin-fixed and paraffin-embedded tissue of 29 CCAs (14 clinically functioning and 15 nonfunctioning). Sanger sequencing was used for the identification of USP8, USP48, BRAF hotspot variants, while semiconductor sequencing with Ion AmpliSeq TP53 Panel was used for analysis of TP53 sequence.
resultsUSP8 variants were found in 2 CCA patients with Cushing's disease (CD), whereas 3 TP53 variants were identified in 1 CCA patient with CD and 2 patients with clinically nonfunctioning CCAs. USP8 variants are less frequent in clinically functioning CCAs than functioning sparsely and densely granulated corticotroph tumors (p = 0.0271). TP53 variants are more common in CCAs as compared to other histological subtypes (p = 0.0164). One BRAF V600E variant and no USP48 variant were found.
conclusionCCAs have slightly distinct mutational profile then other histological subtypes of cPAs. Since clinical relevance of TP53 variants in corticotroph tumors was already documented, testing toward TP53 sequence changes in patients with CCAs should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.